Gilead, a research-based biopharmaceutical company, has reported that their new antiviral treatment for COVID-19 Remdesivir, has just been granted an expansion on emergency use authorization (EUA) by the FDA for all patients hospitalized due to COVID-19. Originally approved in May for only patients who were severely afflicted with COVID-19, studies have since indicated that Remdesivir effectively and safely treats those with more moderate cases of COVID-19 as well. According the FDA, the benefits of Remdesivir outweigh any potential risks.

Read more here.

More on: